Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SRC
REST API REST API
Homo sapiens
SRC is differentially expressed in 271 experiments: 126 organism parts: liver, blood, ... (124 more);, 214 disease states: normal, acute lymphoblastic leukemia, ... (212 more);, 80 cell types 371 cell lines 40 compound treatments and 75 other conditions.
Synonyms c-src, ASV, SRC1
Orthologs ENSCING00000003850 (Ciona intestinalis)   src (Danio rerio)   SRC (Bos taurus)   Src (Rattus norvegicus)   SRC_CHICK (Gallus gallus)   Src (Mus musculus)   ENSCING00000008550 (Ciona intestinalis)   src (Xenopus laevis)   SRC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oogenesis, cytosol, cell migration, plasma membrane, phosphorylation, protein binding, cellular membrane organization, SH2 domain binding, mitochondrial inner membrane, epidermal growth factor receptor signaling pathway, signal complex assembly, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, receptor binding, blood coagulation, protein domain specific binding, heme binding, ephrin receptor binding, fibroblast growth factor receptor signaling pathway, ATP binding, Ras protein signal transduction, axon guidance, SH3/SH2 adaptor activity, nucleotide binding, kinase activity, protein serine/threonine kinase activity, integrin binding, non-membrane spanning protein tyrosine kinase activity, signal transduction, protein kinase activity, caveola, mitochondrion, intracellular protein kinase cascade, regulation of estrogen receptor signaling pathway, leukocyte migration, positive regulation of ERK1 and ERK2 cascade, regulation of vascular permeability, positive regulation of integrin activation, forebrain development, uterus development, positive regulation of canonical Wnt receptor signaling pathway, response to interleukin-1, interspecies interaction between organisms, regulation of bone resorption, branching involved in mammary gland duct morphogenesis, nerve growth factor receptor signaling pathway, bone resorption, T cell costimulation, platelet activation, protein phosphorylation, ion channel binding, cell junction assembly
InterPro Term SH2, SH3_domain, Prot_kinase_cat_dom, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q71UK5, Q9H7V3, P12931
Search EB-eye ENSG00000197122
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-TABM-125, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (37 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
BT474
2
E-MTAB-62, E-MTAB-37
MCF-7
2
E-GEOD-19639, E-GEOD-20081
SW480
2
E-MEXP-1014, E-GEOD-18005
T47D
2
E-MEXP-440, E-MTAB-62
PC3
1
2
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
365 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-GEOD-360, E-GEOD-20677, ... (46 experiments)

Factor Value U/D Experiments
CD4+ T cell
3
E-MTAB-24, E-MTAB-25, E-TABM-145
2
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
CD8+ T cell
1
2
E-MTAB-25, E-TABM-145, E-AFMX-5
stromal cell
1
2
E-MEXP-2034, E-GEOD-10797, E-GEOD-1460
resting natural killer cell
1
E-TABM-702
74 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (64 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-995, E-MTAB-62, E-GEOD-1729
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
colorectal carcinoma
2
E-GEOD-23878, E-MTAB-37
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-62
208 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (24 experiments)

Factor Value U/D Experiments
none
4
7
E-MEXP-1230, E-GEOD-5824, E-TABM-868, E-GEOD-412, E-GEOD-5099, ... (11 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
control
1
2
E-GEOD-3284, E-GEOD-7664, E-GEOD-5339
phenol
1
E-GEOD-6907
rapamycin
1
E-GEOD-5824
Cxcl12
1
1
E-GEOD-7307
34 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-17636, E-GEOD-3982

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-21521

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922, E-TABM-147

Processing time: 0.262 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM